[Epidemiological specificity and clinical aspects of depression in the woman].
Explore the source record for details and available documents.
Adult↗
Biomedical subjects
E Corruble
Publications and source records attributed to E Corruble.
Clozapine treatment following blood dyscrasia.
Explore the source record for details and available documents.
Antipsychotic Agents↗
Psychosis associated with elevated trough tacrolimus blood concentrations after combined kidney-pancreas transplant.
Explore the source record for details and available documents.
Adult↗
Does increasing dose improve efficacy in patients with poor antidepressant response: a review.
OBJECTIVE: Therapeutic strategies in depressed patients with no or partial response to adequate first-line antidepressant medication remain a matter of concern. This paper focuses on the strategy of dose increase. METHOD: This review was based on a systematic Medline search of papers dealing with antidepressant dose issues in major depression since the 1960s. RESULTS: The strategy of dose increase is poorly studied in clinical trials. CONCLUSION: Until this strategy is better studied, caution is advised in its use. However, antidepressants for which this strategy seems to be the most relevant are tricyclic drugs and serotonin and noradrenaline reuptake inhibitors. These results are discussed both in terms of therapeutic strategies for the clinician and in terms of clinical research.
Antidepressive Agents↗
[Anxiety disorders and somatic diseases].
Anxious disorders and general medical conditions are often associated both in general population and in primary care. Several etiopathological mechanisms may explain this association. Anxious disorders in medical patients are not enough recognized and treated. Treatment of both disorders should enable to relieve patient's distress, to improve his quality of life and prognosis of both disorders.
Anti-Anxiety Agents↗
Agreement between 'time-blind' and 'time-non-blind' assessments of depressive symptomatology.
In a 4-week study, two methods were used simultaneously in the assessment of depressive symptomatology with videotaped structured clinical interviews: a 'time-non-blind' (TNB) method (chronological order, observer aware of the previous duration of drug treatment) and a 'time-blind' (TB) method (no chronological order, rater unaware of the previous duration of treatment). Sixty newly admitted depressed inpatients with Montgomery-Asberg Depression Rating Scale scores higher than 20 were assessed before (D0), after 10 days (D10) and after 28 days (D28) of antidepressant treatment. Agreement between TNB and TB methods on the Montgomery-Asberg Depression Rating Scale, measured by intra-class correlation coefficients, was good at D0 (0.68), excellent at D10 (0.81) and D28 (0.86), but not significantly different between D0, D10 and D28. The statistical method of Bland and Altman (1986) was also used to evaluate the degree of agreement. Results of this second analysis were in accordance with the intra-class correlation coefficient results, and showed significantly (P < 0.05) higher D0-D28 and D10-D28 intrasubject changes with the TB method, which were largely accounted for by some particular items (inner tension, pessimism, lassitude). With the Clinical Global Impression-Severity score, the Bland and Altman method failed to show significant differences between the two methods, and compared with the Montgomery-Asberg Depression Rating Scale, intra-class correlation coefficients were lower with larger confidence intervals, suggesting that global ratings are less reliable than itemized symptom ratings.
Adolescent↗
Impulsivity: a relevant dimension in depression regarding suicide attempts?
BACKGROUND: This study focuses on clinical impulsivity in depressed patients, regarding suicide attempts. METHODS: Fifty depressed in-patients were assessed for impulsivity with the Impulsivity Rating Scale and the Baratt Impulsivity Scale, at admission (W0) and after 4 weeks of treatment (W4), with special attention to suicide attempts. RESULTS: In the whole sample, impulsivity scores decreased significantly between W0 and W4. The scale and the questionnaire correlated slightly with each other, suggesting some differences in impulsivity assessment between patients and clinicians. The two subgroups of patients, suicide attempters (SA) (n = 16) and non-suicide attempters (NSA) (n = 34), were different neither in terms of sample characteristics and antidepressant treatments nor in terms of depression and general psychopathology assessments. However, SA patients scored higher on the impulsivity scale and questionnaire than NSA patients, both at W0 and W4. These results suggest first that impulsivity may be both a trait and a state in depressed suicide attempters and second that it may be relevant in terms of suicide attempts in depression.
Adult↗
IDS-C and IDS-sr: psychometric properties in depressed in-patients.
Sixty-eight depressed in-patients were assessed at admission (DO), and after 5 days (D5), ten days (D10) and 28 days (D28) of antidepressant treatment, with the Inventory for Depressive Symptomatology-Clinician (IDS-C) and the Inventory for Depressive Symptomatology-Self-Rated (IDS-SR) (Rush et al., 1986), the Montgomery and Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979) and the depression factor of the Symptom Check List (SCL-90R) (Derogatis, 1977), in order to assess IDS-C and IDS-SR psychometric properties in depressed in-patients and to compare IDS-C to MADRS and IDS-SR to the SCL-90R depression factor. Most of the IDS-C and IDS-SR items were significantly correlated to the final score and the Cronbach alpha coefficients were high (0.75 for the IDS-C and 0.79 for the IDS-SR). Principal Component Analyses (PCA) showed three factors for both IDS-C and IDS-SR: 'depression', 'anxiety/arousal' and 'sleep/appetite'. These results suggest satisfactory internal consistency of IDS-C and IDS-SR. Concurrent validity of the IDS-C with the MADRS was high (r = 0.81), as well as concurrent validity of the IDS-SR with the SCL-90R depression factor (r = 0.84). Concerning sensitivity to change, the four scales were able to discriminate between different levels of severity of depression. Moreover, considering paired t-tests on score changes, IDS-C sensitivity to change may be higher than MADRS sensitivity to change, this phenomenon being related to the number of items and degrees but not to the item contents. Contrary to IDS-C and MADRS, IDS-SR and SCL-90R depression factor were not different in terms of sensitivity to change. Finally, psychometric properties of IDS-C and IDS-SR in depressed in-patients are satisfactory and close to those obtained in depressed out-patients. The high sensitivity to change of the IDS-C may be an advantage for this scale as compared to the MADRS, especially in antidepressant drug trials.
Adult↗
[Is there a relationship between clinical efficacy and antidepressant dosage in major depression?].
Several methodological approaches enable to study dose-efficacy relationships with antidepressants: dose range studies with or without placebo, studies of dose augmentation in non responders, meta-analyses and concentration-efficacy studies. With tricyclic antidepressants, published data on dose-efficacy relationships are relatively scarce but often show that the higher dose is more efficacious than the lower dose. Results of concentration-efficacy studies show heterogeneity between tricyclic antidepressants. With selective serotonine reuptake inhibitors, systematic dose-efficacy and concentration-efficacy studies are available. They show that there is neither dose-efficacy nor concentration-efficacy relationships with SSRI. Venlafaxine has been systematically studied for a dose-efficacy relationship and results show a linear dose-efficacy relationship. Practical implications of these results are discussed.
Antidepressive Agents, Second-Generation↗
A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients.
This double-blind, randomised, multicentre study compared the antidepressant efficacy and safety of two doses of milnacipran (100 mg/day and 200 mg/day) and fluoxetine (20 mg/day) in 289 inpatients with endogenous depression. After a placebo washout period of 4-7 days, assessments were performed weekly during the first 4 weeks, and then after 6, 8 and 12 weeks, using the 17-item Hamilton Depression Rating Scale (HDRS), the Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression (CGI). HDRS total score was reduced by a mean of 14.8 in the milnacipran 100 mg/day group, 12.9 in the milnacipran 200 mg/day group and 12.1 in the fluoxetine 20 mg/day group. MADRS total score decreased by 17.4, 15.8 and 14.6, respectively. No significant difference could be shown between the three treatment groups for either the HDRS or MADRS total scores. However, the time-by-time change showed a trend in favour of milnacipran 100 mg/day, which was found significantly superior to fluoxetine at day 28 for several converging parameters (MADRS, CGI-3). Overall, efficacy ratings for all parameters were highest for milnacipran 100 mg/day, followed by milnacipran 200 mg/day and fluoxetine 20 mg/day. Side-effect profiles were not significantly different between groups except for a significantly greater frequency of dose-related increase in heart rate > or = 100 bpm in milnacipran recipients and a significantly greater weight loss in fluoxetine recipients.
Adolescent↗
Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors.
To investigate adaptative changes of 5-HT2A receptors induced by SSRIs, six patients chronically treated for a depressive episode (four with fluoxetine, two with fluvoxamine) were studied with PET and [18F]setoperone. They were compared to eight untreated depressive patients. The mean frontal to cerebellum radioactivity concentration ratio, an index of the [18F]setoperone specific binding to 5-HT2A receptors, was higher in treated than in untreated patients, when age was taken into account. This suggests that chronic treatment by SSRIs could induce an up-regulation of the 5-HT2A receptors, and that 5-HT2A receptor down-regulation is not a common mechanism for the therapeutic effects of all serotoninergic antidepressive drugs.
Adult↗
Comorbidity of personality disorders and unipolar major depression: a review.
The association of major depressive disorders with personality disorders is relevant in terms of clinical, therapeutic and prognostic aspects. However, the prevalence of this association remains unclear. This may be due to methodological considerations. Nonetheless, it could be estimated from this review that 20% to 50% of inpatients and 50% to 85% of out-patients with a current major depressive disorder have an associated personality disorder. Cluster B personality disorders, in particular borderline (10-30%), histrionic (2-20%) and antisocial (0-10%), seem to be overrepresented, even if the narcissistic one is rare (less than 5%). The main characteristic of Cluster C personality disorders is the great variability of results across studies, except for the obsessive compulsive personality disorder, whose prevalence is consistent and rather high (0-20%). Cluster A personality disorders are an heterogeneous group, since the prevalence of schizotypal personality disorder is rather high (0-20%), the prevalence of paranoid personality disorder is low (less than 5%) and the prevalence of schizoid personality disorder is quite variable from one study to another. The prevalence of personality disorders among patients with a lifetime major depression has been insufficiently studied, although it may concern half of these patients. The prevalence of current of lifetime major depression among patients with a personality disorder has not been sufficiently studied and results are very scattered. Also, the coexistence of personality disorder and major depression is frequent, and this review emphasizes the heterogeneity of the personality styles associated with major depression. Finally, an optimization of methods and the adjunction of a dimensional point of view to the categorical approach may help to study the comorbidity of major depression and personality disorders and its consequences.
Comorbidity↗
[Biological factors and resistance to antidepressive agents].
Concerning depressive disorders, biological factors remain relatively unknown. However, they might first be risk factors for depressive disorders and secondly could decrease the response to antidepressants. We studied hypothyroidism, diabetes and hypothalamic-pituitary-adrenal axis disorders. In terms of neurotransmitters, beta-adrenergic dysfunction may be involved in hypothyroidism and diabetes whereas a serotonergic dysfunction may be involved in hypothalamic-pituitary-adrenal axis disorders.
Animals↗
[Pharmacologic effects of mechanism of action of antidepressive agents].
Explore the source record for details and available documents.
Antidepressive Agents↗
How to improve the risk-benefit ratio of antidepressants.
To improve the risk associated with present antidepressant drugs, it is necessary to choose drugs that are selective and well tolerated in overdose, to look for contraindications, to adapt the dose progressively, to inform and supervise patients adequately, and to deal with risks due to the main pharmacological effects (anxiety, nervousness, sleep disturbances, suicide). With new drugs, risk improvement will probably be the result of greater selectivity. Improvements in efficacy could emerge during the development of new drugs, based on the monoaminergic and non-monoaminergic hypotheses. Much progress could be made, however, by questioning present practices. Optimizing dose, duration of treatment, co-medication, strategies for non-responders, and compliance, decreasing onset of action and targeting patients may help improve the efficacy of present antidepressant drugs.
Antidepressive Agents↗
Concordance between self-report and clinician's assessment of depression.
In order to assess differences between self-assessment and clinician's assessment of depression, 64 depressed in-patients were assessed for depressive symptomatology at admission (D0), 10 days (D10) and 28 days (D28) after the beginning of antidepressant treatment, using the Inventory for Depressive Symptomatology Clinician Rated (IDS-C) and the Inventory for Depressive Symptomatology Self-Rated (IDS-SR). Associated symptoms (SCL-90R) were assessed at D0 and personality dimensions (TCI) at D28. Although agreement was high between IDS-C and IDS-SR total scores, D0, D0-D10 and D0-D28 total scores were significantly different between IDS-C and IDS-SR, showing a higher sensitivity to change for IDS-C as compared to IDS-SR. Differences between IDS-C and IDS-SR were due mostly to mood items and not to somatic items. Discrepancies between self-assessment and clinician's assessment of depressive symptomatology were linked neither to age, sex, familial status, single/recurrent and length of episode, nor to depression severity, but to associated symptoms and, to a lesser extent, personality dimensions: patients over-estimating their depressive symptomatology change relative to the psychiatrist tended to score high on phobic anxiety, Cooperativeness (especially Social Acceptance) and Self-Transcendence (especially Self-forgetfulness) and vice-versa.
Adult↗
Pain complaints in depressed inpatients.
Pain complaints were assessed in 150 depressed inpatients at admission (D0), after 10 days (D10) and 28 days of treatment (D28) using the Symptom Check List, 90 items, revised version (SCL-90R). Pain complaints were present in 92% of patients at D0, several pain complaints being reported by 76% of patients. Headache and chest pain were more frequent in women, whereas myalgia and numbness were more frequent in men. Pain complaints were related to depressive and anxious complaints as assessed by the SCL-90R, but not to age, suicide attempts and depression severity as assessed by the psychiatrist. Pain complaints decreased between D0 and D10, whereas depression scores decreased both between D0 and D10 and between D10 and D28. As compared to responders to treatment at D28, nonresponders had lower Montgomery and Asberg Depression Rating Scale scores at D0 and higher pain complaint scores at D0 and D10.
Adolescent↗
[Personality factors in depressive disorders: contribution of the psychobiologic model developed by Cloninger].
The psychobiological model of personality developed by Cloninger, including four dimensions of temperament and three dimensions of character, allows to explore personality factors associated with depressive disorders. The three main dimensions of temperament are Novelty Seeking (NS), ie the tendency towards excitement in response to novel or rewarding stimuli, Harm Avoidance (HA) hypothesized to represent the tendency to respond intensely to signals of adverse stimuli, and Reward Dependence reflecting the tendency to respond intensely to signals of reward and to maintain behavior previously associated with reward. These personality traits are hypothetically related to underlying neurotransmetter systems (especially NS to dopaminergic function and HA to serotonergic function). The two main dimensions of character are Self-Directedness (SD) and Cooperativeness (C), measuring maturity traits respectively concerning individual and social adaptation; thus they are negatively correlated with the risk of personality disorder for a given patient. Many studies have been carried out with the Temperament and Character Inventory (TCI), or with the previous Tridimensional Personality Questionnaire (TPQ), in depressive disorders with cross-sectional but also with short-term and long-term longitudinal designs. They show primarily that patients with history of depressive disorders, even in euthymic phase, have very high Harm Avoidance scores. In prospective studies conducted in depressive patients, even after remission of the depressive episodes, the Harm Avoidance scores are lower than before treatment, but still elevated compared to the general population. The patients who fail to respond to antidepressant treatments have generally higher Harm Avoidance scores before treatment than the others. Overall, various results support four types of potent relationships between Harm Avoidance and depression: an influence of state on trait measure, a pathoplastic effect of Harm Avoidance on depressive expression, a vulnerability model (Harm Avoidance representing a susceptibility factor for depression), and a scar model with elevated Harm Avoidance scores even after remission of acute depressive symptoms. Other temperament dimensions, Novelty Seeking and Reward Dependence, are not consistently associated with depression characteristics nor affected by state effects, but Self-Directedness character dimension is often low when compared to subjects without depressive disorders, reflecting maladaptive personalities frequently associated to depressive disorders. Some studies suggest that low Self-Directedness scores can be predictive of suicidal behaviors. In cross-sectional studies, Harm Avoidance scores are highly positively correlated with depression intensity (r=0.23 to 0.67) and Self-Directedness scores are highly negatively correlated with depression (r=- 0.37 to - 0.60). Some studies suggest that the temperamental dimensions assessed by the TCI could have a predictive value for the response to antidepressants treatments, but this result is controversial and needs further research. For example, a study conducted in 84 patients with major depressive disorder showed that temperament type based on TPQ traits explained 25% of the response to treatment variance: patients with high scores on both Harm Avoidance and Reward Dependence had a favourable response to either clomipramine or desipramine. Studies of the relationship of temperament dimensions to biological markers of depression have also been published. It has been shown for example that Reward Dependence and Harm Avoidance scores are significantly predictive of morning hypercortisolemia in depressed subjects. More specifically, correlations have been obtained between platelet serotonergic markers (5-HT2a receptors) and Harm Avoidance scores also in depressed patients. In conclusion, Harm Avoidance seems to be a vulnerability factor or at least an associated factor to depressive disorders. This temperament dimension is supposed to be highly heritable, and to be linked to the serotonergic system variations.
Brain↗